Document is current

Article History

Received: 11 April 2022

Accepted: 5 November 2022

First Online: 29 December 2022

Declarations

:

: This is a retrospective study, which investigates past treatment by going back through medical records. In addition to being a study based on past medical information, most of the patients have already died because the study targets patients with bone metastases from lung cancer, and it is practically impossible to obtain the consent of each patient to participate in the study. We used the standard and best practices at the time of treatment, and we obtained written consent for every treatment.All procedures performed in studies involving human participants were in accordance with the ethical standards of the institutional and/or national research committee and with the 1975 Helsinki declaration and its later amendments or comparable ethical standards. Instead, we publish our research on our website and the hospital's bulletin board.The procedure of this study and the collection, analysis, and publication of the data were approved by the Shizuoka Cancer Center Review Board (ID 26-J109-26–1-3), and the requirement for written informed consent and the consent to participate was waived due to the retrospective design of the study.

: Not applicable.

: T. Takahashi received research funding and honoraria for a lecture from Astrazeneka K.K., H. Murakami received research funding and honoraria for a lecture from Astrazeneka K.K., Daiichi Sankyo, Novartis, and H. Harada received honoraria for a lecture from Astrazeneka K.K., Pfizer Japan Inc., Eli Lilly and Company, MSD K.K., and Brainlab AG. The other authors have no conflict of interest.